D-dimers

DD-XLink-mab

Monoclonal antibody against crosslinked fibrin ("D-dimer")

Order
Quantity
Price
Status
100 µg 365 € available


Documents
Art. No. A076
Background info After proteolytic activation by thrombin, FXIIIa modifies the soft fibrin clot and thereby introducing covalent bonds. First, cross-linking between abutting γ-chains of fibrin is catalyzed and subsequently α2-antiplasmin is incorporated to further increase the resistance against fibrinolysis. Plasmin catalyses the retarded clot dissolution and the release of crosslinked fibrin degradation products (xFDPs / D-dimer). Monoclonal “D-dimer” antibodies (e.g. DD-3B6/22) are commercially available and are used in In Vitro Diagnostics (IVD) to exclude thromboembolic events. However, these monoclonals do not detect the crosslink itself but address a portion of polypeptides within the D-domain after plasmin degradation that are conformationally reactive. Zedira scientists developed a monoclonal antibody which directly recognizes the crosslinked fibrin neoepitope (DD-XLink-mab).

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Host Mouse
Isotype IgG2b κ
Immunogen Human fibrin peptides cross-linked with plasma factor XIIIa
Specificity Specific for clot derived xFDPs (crosslinked Fibrin Degradation Products) Minor reactivity with fibrinogen degradation products (FDPs) cannot be excluded (compare to ELISA data, see figure 3 in PDS).
Formulation The antibody is stored in PBS, 150 mM NaCl (pH 7.4), 0.02% sodium azide
Working dilutions Optimal dilutions should be determined by the end user. E. g. for Western-Blotting: 1 / 3,000 to 1 / 10,000 should be suitable
Storage Store at 2 – 8 °C
Note NOTE INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland